Caribou's CRISPR Cancer Therapies Show Durability, Rivaling Standard Care

BERKELEY, CA – February 04, 2026 – Caribou Biosciences (Nasdaq: CRBU) today unveiled compelling new data for its two leading "off-the-shelf" CAR-T cell therapies, sending a strong signal that the next generation of cancer treatment may be closer than ever. At the prestigious 2026 Tandem Meetings, the company presented late-breaking results for vispa-cel and CB-011, demonstrating deep and durable responses in patients with aggressive blood cancers. The findings suggest Caribou's advanced CRISPR gene-editing techniques could overcome critical hurdles that have long challenged the field of allogeneic, or universal, cell therapy.

The data, building on initial results disclosed in late 2025, positions the Berkeley-based company as a formidable player in the race to develop effective, readily available treatments for large B cell lymphoma and multiple myeloma.

Vispa-cel Rivals Personalized Therapy in Lymphoma

In a significant development for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL), Caribou’s vispa-cel therapy demonstrated efficacy and durability on par with existing autologous CAR-T therapies. Autologous treatments, which are custom-made from a patient's own cells, are effective but plagued by lengthy manufacturing times, high costs, and potential for production failure.

Updated results from the ANTLER phase 1 clinical trial, presented in a poster session, focused on a cohort of patients with second-line large B cell lymphoma (2L LBCL). The data was striking: vispa-cel achieved an 82% overall response rate (ORR) and an impressive 64% complete response (CR) rate. Perhaps more importantly, the responses appear to be lasting. The 12-month progression-free survival (PFS) rate stood at 51%, with the median duration of response not yet reached, indicating a strong trend towards long-term disease control. Highlighting this durability, one patient from the trial has now remained in a complete response for three years.

"Selection of both of Caribou’s allogeneic CAR-T cell programs as late-breaking presentations underscores the strength of the safety, efficacy, and durability data and the potential impact these off-the-shelf CAR-T cell therapies can have in addressing urgent patient need,” said Rachel Haurwitz, PhD, Caribou’s president and CEO, in a statement.

The science behind vispa-cel is a key part of its success. To Caribou's knowledge, it is the first allogeneic CAR-T therapy in the clinic to feature a PD-1 knockout. Using its proprietary Cas12a chRDNA genome-editing platform, Caribou engineers the donor T cells to remove the PD-1 gene. This "armors" the cells, preventing them from succumbing to premature exhaustion—a common tactic tumors use to evade the immune system. This innovation is designed to allow the CAR-T cells to fight cancer more persistently. The therapy has already garnered Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations from the FDA.

Immune Cloaking Shows Promise in Multiple Myeloma

Caribou’s second lead candidate, CB-011, also made waves with new data from its CaMMouflage phase 1 trial for patients with heavily pre-treated relapsed or refractory multiple myeloma (r/r MM). An oral presentation detailed how the therapy's expansion within the body correlated directly with deep and lasting responses, a crucial indicator of therapeutic success.

Among a cohort of 12 BCMA-naïve patients treated at the dose selected for expansion, CB-011 achieved a 92% overall response rate. An exceptional 75% of these patients achieved a complete response or better, with 91% testing negative for minimal residual disease (MRD), a highly sensitive measure of cancer's disappearance.

CB-011's engineering is designed to solve one of the most fundamental challenges of allogeneic therapy: immune rejection. The patient's immune system is naturally programmed to attack foreign cells, which can quickly eliminate donor-derived CAR-T cells. Caribou's solution is a sophisticated "immune cloaking" strategy. The company uses CRISPR to knock out the B2M gene, effectively removing the primary flags (HLA class I molecules) that identify the cells as foreign. It then inserts a gene for a B2M–HLA-E fusion protein, which acts as a "do not attack" signal to the patient's natural killer (NK) cells, providing a second layer of protection. This dual approach aims to make the CAR-T cells invisible to the patient's immune system, allowing them to survive longer and eradicate the myeloma cells. CB-011 has also received Fast Track and Orphan Drug designations from the FDA.

Redefining the Future of Cell Therapy Access

The data presented by Caribou addresses the central promise of allogeneic cell therapy: to democratize access to one of modern medicine’s most powerful cancer treatments. Current FDA-approved CAR-T therapies are autologous, a bespoke process that can take weeks. For patients with rapidly advancing disease, this wait can be untenable. Furthermore, the complex, individualized manufacturing process makes these treatments extraordinarily expensive and logistically challenging to administer.

"Off-the-shelf" therapies like vispa-cel and CB-011 are manufactured in advance from the cells of healthy donors and stored for immediate use. This model could dramatically reduce treatment times, lower costs through scaled production, and provide a standardized, high-quality product for a much broader patient population. However, the field has been stymied by the dual challenges of host-versus-graft rejection (the patient's body rejecting the therapy) and ensuring the therapy is durable enough to provide a lasting cure.

Caribou’s latest results suggest its precision genome-editing platform is making tangible progress against these barriers. By engineering cells to be more persistent (PD-1 knockout) and to evade rejection (immune cloaking), the company is tackling the core scientific problems head-on. This approach is what separates it in a competitive landscape filled with biotech firms like Allogene Therapeutics and CRISPR Therapeutics, all racing to bring a universal CAR-T product to market. The strength of this new data, combined with a strategic focus on its lead programs and a reported cash runway to support development, solidifies Caribou's position as a key innovator to watch in the evolving story of cellular immunotherapy.